Marengo Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
840 Memorial Dr Ste 4, Cambridge, Massac...Phone Number
(617) 917-4980Website
www.marengotx.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Marengo Therapeutics
Marengo Therapeutics operates a first-in-class immune activation platform that selectively activates and expands the right immune cells to mount potent anti-tumor responses for long-term protection against cancer. Established in 2015, Marengo Therapeutics is headquartered in Massachusetts.Explore more
Marengo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Marengo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Marengo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Marengo Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Marengo Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Marengo Therapeutics
Check out if Marengo Therapeutics is spiking on competitors!
Product Launch: Get notified when Marengo Therapeutics launches new products
Check if Marengo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Marengo Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Marengo Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Marengo Therapeutics
Compare insights from companies similar to Marengo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Marengo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Marengo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Marengo Therapeutics.
Marengo Therapeutics financials insights
Gather financial insights about Marengo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$80M
Marengo Therapeutics Tech Stack
A closer look at the technologies used by Marengo Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Facilities Relocation / Expansion
Marengo Therapeutics is planning to move offices in January 2027. The move will impact approximately 30 employees at the existing office located at 840 Memorial Drive, 4th Floor, Cambridge, MA.
Facilities Relocation/Expansion
Left Company
Executive Move
Executive Moves, Left Company
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Project
Request for Proposal (RFP), Telemedicine
Marengo Therapeutics News & Media
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
First partnered TriSTAR program advances into IND-enabling development Industry-leading expert in T-cell engager discovery and immune-cell activation, Saso Cemerski, joins as Senior Vice President, Head of Immunology, to accelerate expansion of Marengo's precision Vβ-directed T-cell...Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026
Encouraging Phase 2 clinical activity with confirmed complete responses observed in heavily pretreated metastatic breast cancer across both TNBC and HR+/HER2- subtypes First public disclosure of clinical stage Ipsen-partnered STAR program IPN01203 CAMBRIDGE, Mass., April 17, 2026...Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer Early anti-tumor activity observed in majority...Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
20% ORR and 80% DCR observed as monotherapy in TMB-H tumors across seven major solid tumor types, including colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), head and neck, and bladder cancers Clinical activity was consistent across all subgroups and independent of prior...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Marengo Therapeutics
Sign Up For FreeTo access detailed company insights
Marengo Therapeutics operates a first-in-class immune activation platform that selectively activates and expands the right immune cells to mount potent anti-tumor responses for long-term protection against cancer. Established in 2015, Marengo Therapeutics is headquartered in Massachusetts.... Read More
